JP2019513826A - 放射線療法の改善 - Google Patents

放射線療法の改善 Download PDF

Info

Publication number
JP2019513826A
JP2019513826A JP2019503597A JP2019503597A JP2019513826A JP 2019513826 A JP2019513826 A JP 2019513826A JP 2019503597 A JP2019503597 A JP 2019503597A JP 2019503597 A JP2019503597 A JP 2019503597A JP 2019513826 A JP2019513826 A JP 2019513826A
Authority
JP
Japan
Prior art keywords
individual
tumors
alkyl
irradiated
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513826A5 (enExample
Inventor
ケリー グレイアム
ケリー グレイアム
Original Assignee
ノクソファーム リミティド
ノクソファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by ノクソファーム リミティド, ノクソファーム リミティド filed Critical ノクソファーム リミティド
Publication of JP2019513826A publication Critical patent/JP2019513826A/ja
Publication of JP2019513826A5 publication Critical patent/JP2019513826A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019503597A 2016-04-06 2017-04-06 放射線療法の改善 Pending JP2019513826A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762461559P 2017-02-21 2017-02-21
US62/461,559 2017-02-21
PCT/AU2017/050299 WO2017173496A1 (en) 2016-04-06 2017-04-06 Radiotherapy improvements

Publications (2)

Publication Number Publication Date
JP2019513826A true JP2019513826A (ja) 2019-05-30
JP2019513826A5 JP2019513826A5 (enExample) 2020-05-21

Family

ID=60000154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503597A Pending JP2019513826A (ja) 2016-04-06 2017-04-06 放射線療法の改善

Country Status (6)

Country Link
US (2) US11229703B2 (enExample)
EP (1) EP3439642A4 (enExample)
JP (1) JP2019513826A (enExample)
AU (1) AU2017247006B2 (enExample)
CA (1) CA3058492A1 (enExample)
WO (1) WO2017173496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
JP2012500809A (ja) * 2008-08-29 2012-01-12 ノボゲン リサーチ ピーティーワイ リミテッド 免疫調節活性

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
MXPA04009896A (es) 2002-04-09 2005-06-17 Novogen Res Pty Ltd Metodos terapeuticos y composiciones que implican estructuras de tipo isoflav-3-eno e isoflavano.
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050154452A1 (en) 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
US8080675B2 (en) * 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1809618B1 (en) 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
ATE532777T1 (de) * 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
US20090131513A1 (en) 2005-03-24 2009-05-21 Novogen Research Pty Ltd. Anti-inflammatory modalities
JP2009508869A (ja) 2005-09-15 2009-03-05 ユーエムディー， インコーポレイテッド シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
WO2008052256A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
EP2160385A4 (en) * 2007-06-29 2010-10-27 Novogen Res Pty Ltd 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND MEDICAMENTS THEREOF AND APPLICATIONS THEREOF
US8729134B2 (en) 2008-11-14 2014-05-20 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2766500A4 (en) * 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
ES2734568T3 (es) * 2013-03-13 2019-12-10 Oncoceutics Inc 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
SG11201604490SA (en) * 2014-02-07 2016-07-28 Novogen ltd Functionalised benzopyran compounds and use thereof
SG10202111808WA (en) 2015-08-11 2021-11-29 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CN108884159A (zh) * 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
AU2017247006B2 (en) * 2016-04-06 2022-05-12 Noxopharm Limited Radiotherapy improvements
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
AU2016401508B2 (en) * 2016-04-06 2020-03-26 Noxopharm Limited Improvements in cancer treatment
EP4035667A1 (en) * 2016-04-22 2022-08-03 Noxopharm Limited Chemotherapy improvements with idronoxil
JP7329860B2 (ja) 2018-06-15 2023-08-21 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｓ－エクオールを用いた乳癌の治療及び予防方法
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
JP2012500809A (ja) * 2008-08-29 2012-01-12 ノボゲン リサーチ ピーティーワイ リミテッド 免疫調節活性

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INT. J. MOL. SCI., vol. 15, JPN6021011589, 2014, pages 927 - 943, ISSN: 0004710777 *
JPN. J. MED. PHYS., vol. 34, no. 2, JPN6021011592, 2014, pages 70 - 78, ISSN: 0004710778 *
がん分子標的治療, vol. 13, no. 4, JPN6021011586, 2015, pages 24 - 28, ISSN: 0004710776 *

Also Published As

Publication number Publication date
US20190262451A1 (en) 2019-08-29
US20220105182A1 (en) 2022-04-07
CA3058492A1 (en) 2017-10-12
AU2017247006A1 (en) 2018-11-01
WO2017173496A1 (en) 2017-10-12
EP3439642A1 (en) 2019-02-13
AU2017247006B2 (en) 2022-05-12
US11229703B2 (en) 2022-01-25
EP3439642A4 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
JP7656012B2 (ja) 肺癌の処置のための抗ｐｄ－１抗体
Brix et al. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences
JP6999577B2 (ja) がんを処置するための抗ｐｄ－１抗体と放射線の組合せ
Crittenden et al. Current clinical trials testing combinations of immunotherapy and radiation
JP2020121978A (ja) 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法
Rini Future approaches in immunotherapy
Al Jarroudi et al. Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases
JP7490361B2 (ja) ｉｎ ｓｉｔｕ免疫調節癌ワクチン接種のための放射性ハロゲン化剤
JP2023179556A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
JP7627259B2 (ja) 抗ｃｄ２５抗体－フタロシアニン色素コンジュゲートおよび抗ｐｄ１抗体を使用したがんの処置のための近赤外（ｎｉｒ）光免疫療法（ｐｉｔ）
Chi et al. Putative abscopal effect in three patients treated by combined radiotherapy and modulated electrohyperthermia
US20220105182A1 (en) Radiotherapy improvements
Teets et al. Avelumab: A novel anti-PD-L1 agent in the treatment of merkel cell carcinoma and urothelial cell carcinoma
Serre et al. Brachytherapy: Perspectives for combined treatments with immunotherapy
Fan et al. The progress of combination therapy with immune checkpoint inhibitors in breast cancer
Osei et al. A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours
JPWO2021113734A5 (enExample)
Klautke et al. PD (L) 1-Inhibitors and Radiation: A Good Combination for Local and Systemic Effects?
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
Chacko et al. ROLE OF SINGLE IMMUNO-ONCOLOGY AGENTS AND COMBINATIONS IN CANCER THERAPY
Hurria Breast cancer: medical management of early stage breast cancer
EA045900B1 (ru) Комбинация антител против pd-1 и облучения для лечения злокачественной опухоли

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927